Lamb Weston Holdings Inc vs Revvity Inc — how do they compare? Lamb Weston Holdings Inc trades at $46.42 (market cap $6.43B), while Revvity Inc trades at $110.1 (market cap $11.87B). The key difference: Revvity Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.26%). Which is the better fit depends on your goals.
| LW | RVTY | |
|---|---|---|
Market Cap | $6.43B | $11.87B |
Sector | Consumer Staples | Technology |
52-Week High | $66.57 | $117.75 |
52-Week Low | $38.48 | $82.26 |
Enterprise Value | $10.40B | $14.36B |
Dividend Yield | 3.26% | 0.26% |
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $47.26, up 1.0% on the day, with a bullish technical signal from moving averages. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue reached $6.45B in 2025, though net income margin compressed to 4.61%. Analyst consensus is a $49.33 price target with a mixed buy/hold rating split. Recent news highlights the company's 'Focus to Win' strategy driving North America volume gains and cost savings, alongside ongoing legal challenges.
LW presents a turnaround story with cost-saving initiatives and market share gains supporting upside potential. However, margin pressures, a pending securities lawsuit, and high debt levels pose significant risks. The stock's valuation at a P/E of 21.88 appears reasonable if earnings growth resumes, but investors face headwinds from competitive and operational challenges.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Trailing returns across standard periods
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →